The UK’s national innovation agency – Innovate UK – has provided funding to Awakn Life Sciences to help bring its ketamine-assisted therapy to alcohol use disorder...
World renowned auction house Christie’s partnered with the Multidisciplinary Association for Psychedelic Studies (MAPS) and leading artists to raise funds that will be donated to MAPS to support the...
Results from the largest longitudinal study investigating the practice of microdosing psilocybin for mental health, and one of the few to use a control group, have...
Cybin has confirmed that it has received a “may proceed letter” and Investigational New Drug Application (IND) clearance from the U.S.
MAPS PBC is entering into a collaboration that aims to bring its novel therapy for PTSD closer to regulatory evaluation.
Breaking Convention’s 11th conference, Worlds Collide, will feature themed panel discussions, art exhibitions and stalls.
Silo Pharma has entered into a commercial evaluation license agreement (CELA) for next-gen liposomes therapeutics to target multiple diseases, including autoimmune disorders.
Mindset Pharma and Canada’s top psychiatric research hospital, CAMH, have entered into a collaboration to build the molecular profile of MSP-1014 compared to psilocybin.
Ceruvia Lifesciences has submitted an FDA Investigational New Drug (IND) Application for its NYPRG-101 Migraine Prevention Program.
The US food and Drugs Administration (FDA) has given approval for MYCO-001 in a recent Investigational New Drug (IND) application, which will now be used in...
Psychedelic Health speaks to the founder of the Psychedelic Access and Research European Alliance (PAREA), Tadeusz Hawrot, about how the organisation aims to facilitate discussions around...
Ohio State University is launching The Center for Psychedelic Drug Research and Education (CPDRE).
